Founded in 2008, Axio Biosolutions operates in Health Tech industry. Initially focused on creating hemostatic solutions, the company has expanded its product offerings to serve both trauma and surgica...
Funding stage:
Series B
Last funding:
26/07/2021
Total funding:
$21.00 Mn+
Revenue:
Investors
Employee count:
128
Last 90d
128
Last 90d
Web traffic:
2.84K
2.84K
Last 30d
Last 30d
Glassdoor Rating:
Axio Biosolutions: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders2
Latest Filing Date30 March 2023- Funding Events1
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Axio Biosolutions
As of 31 March 2023, Axio Biosolutions's equity is held by 2 shareholders, with the top three being Advamedica Inc and Leo Sebastian Mavely.
Advamedica Inc holds the largest stake in Axio Biosolutions at 100.0% as of 31 March 2023.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links